Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 23,064 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $70.13, for a total transaction of $1,617,478.32. Following the completion of the sale, the chief operating officer now directly owns 61,361 shares in the company, valued at $4,303,246.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven J. Kafka also recently made the following trade(s):

  • On Tuesday, January 2nd, Steven J. Kafka sold 157 shares of Foundation Medicine stock. The shares were sold at an average price of $64.00, for a total transaction of $10,048.00.

Shares of Foundation Medicine Inc (FMI) opened at $64.85 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. Foundation Medicine Inc has a 12 month low of $22.40 and a 12 month high of $75.20. The stock has a market cap of $2,350.00, a PE ratio of -14.51 and a beta of -0.03.

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Foundation Medicine by 8.2% during the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after acquiring an additional 47,843 shares in the last quarter. Peregrine Capital Management LLC purchased a new stake in shares of Foundation Medicine during the 3rd quarter worth about $13,299,000. TIAA CREF Investment Management LLC boosted its stake in shares of Foundation Medicine by 9.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 39,000 shares of the company’s stock worth $1,550,000 after acquiring an additional 3,490 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Foundation Medicine by 215.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,786 shares of the company’s stock worth $393,000 after acquiring an additional 6,686 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Foundation Medicine by 33.3% during the 3rd quarter. Macquarie Group Ltd. now owns 106,603 shares of the company’s stock worth $4,285,000 after acquiring an additional 26,603 shares in the last quarter. 33.12% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have commented on FMI shares. Zacks Investment Research lowered shares of Foundation Medicine from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, Goldman Sachs Group initiated coverage on shares of Foundation Medicine in a research note on Monday, January 29th. They set a “neutral” rating and a $73.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $52.25.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Foundation Medicine Inc (FMI) COO Sells 23,064 Shares of Stock” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/02/11/insider-selling-foundation-medicine-inc-fmi-coo-sells-23064-shares-of-stock.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.